Condition: System Lupus Erythematosus(SLE) · Scleroderma · Myasthenia Gravis (MG) · Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
A FIH, single arm, open-label, Investigator Initiated Trial (IIT) study to evaluate the safety and tolerability of EVM18001 in the treatment of active refractory autoimmune diseases (SLE, MG, and SSc), and determine the recommended dose for subsequent treatment. At the same time, the PK/PD characteristics of EVM18001 will be evaluated, preliminary efficacy will be observed, and related biomarkers and immunogenicity will be explored.
This description comes directly from the study's public registry record.
Qiubai Li, professor · 85726808 · qiubaili@hust.edu.cn
Di Wu · 18790696175 · 373181302@qq.com
Always discuss trial participation with your own doctor first.
| Union hospital Tongji medical college Huazhong university of science and technology | Wuhan, Hubei, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07470151